Giant Lymph Node Hyperplasia Clinical Trial
Official title:
Clinical and Virologic Response to HHV-8 Associated Multicentric Castleman's Disease to Valganciclovir
The purpose of the study is to learn whether people who are experiencing an MCD (multicentric Castleman's Disease) flare will improve after taking valganciclovir. MCD is a type of inflammatory disease associated with Human Herpesvirus 8 (HHV-8). Valganciclovir is FDA approved for treating a different type of Human Herpesvirus, but not approved for the treatment of HHV-8. It is therefore considered experimental in this study.
All participants will undergo an initial screening appointment. At this visit, participants
will be tested for Human Herpesvirus 8 (HHV-8), the virus that is associated with MCD, and
we will review participants' medical history and medical records to determine whether he/she
has MCD. If participants do not live within the Seattle area, this visit may occur over the
phone.
Those who qualify for the study will be followed for up to 2 years. During that 2 year
period, participants will be asked to collect oral swabs once a week and have blood drawn
monthly. If subjects do not live within the Seattle-area, they will be asked to ship these
samples to UW for testing. We will provide subjects with instructions for these shipments.
This will be done at no cost to the participant.
If during the 2 year period the participant experiences a MCD flare, he/she will be admitted
to the University of Washington Medical Center's Clinic Research Center for 14-days. If the
participant does not live within the Seattle-area, all travel expenses will be covered.
The study will enroll a total of 8 patients who will receive open-label valganciclovir for
14-days. Everyday during the hospitalization, participants will have blood drawn (to check
your HHV-8 levels), 1 oral swab will be collected and a general physical exam will be
performed.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01441063 -
Tocilizumab for KSHV-Associated Multicentric Castleman Disease
|
Phase 2 | |
| Recruiting |
NCT02817997 -
International Registry for Patients With Castleman Disease
|
||
| Completed |
NCT00412321 -
A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
|
Phase 1 | |
| Terminated |
NCT00127569 -
Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy
|
Phase 2 | |
| Withdrawn |
NCT02871050 -
Castleman Disease Collaborative Network Biobank
|
||
| Completed |
NCT02853968 -
Unlock the Cell: Castleman's Disease Flow Cytometry Study
|